MedTrace Logo

Multiple-Ascending Dose Study

NCT00892840 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2011-02-11

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of BMS-820836 after multiple doses

Conditions

Interventions

DRUG

BMS-820836

Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days

DRUG

Placebo

Oral Solution, Oral, 0 mg, Once daily, 14 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892840 on ClinicalTrials.gov